Home/ Stocks/ PROK

ProKidney Corp. Class A Ordinary Shares

PROK XNAS

$1.86 +0.01 (+0.53%) ▲ 15-min delayed

Open

$1.90

High

$1.91

Low

$1.85

Volume

719.1K

Market Cap

$264.10M

About ProKidney Corp. Class A Ordinary Shares

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 231 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$893.0K	$-151,612,000	N/A
FY 2025	$893.0K	$-151,612,000	N/A
Q3 2025	$217.0K	$-35,843,000	N/A
Q2 2025	$221.0K	$-36,965,000	N/A

Related Market News

No specific coverage for PROK yet. Check out our latest market news or earnings calendar.

Get PROK Alerts

Stay ahead with breaking news, price alerts, and expert analysis on ProKidney Corp. Class A Ordinary Shares.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.